News
ENTA
44.62
+1.90%
0.83
Newsflash: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Analysts Have Been Trimming Their Revenue Forecasts
Today is shaping up negative for Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shareholders, with the analysts...
Simply Wall St. · 11/23 10:09
RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Lowers Price Target to $54
Benzinga · 11/22 12:39
RBC Cuts Price Target on Enanta Pharmaceuticals to $54 From $65, Maintains Sector Perform Rating
RBC Cuts Price Target on Enanta Pharmaceuticals to $54 From $65, Maintains Sector Perform Rating
MT Newswires · 11/22 08:15
BRIEF-Enanta Pharmaceuticals Reports Financial Results For Fiscal Fourth Quarter And Full Year
Reuters · 11/21 21:07
Enanta Pharmaceuticals Q4 EPS $(1.27) Beats $(1.35) Estimate, Sales $20.32M Miss $22.86M Estimate
Benzinga · 11/21 21:03
Enanta Pharmaceuticals Fiscal Q4 Loss Widens as Revenue Drops
Enanta Pharmaceuticals Fiscal Q4 Loss Widens as Revenue Drops
MT Newswires · 11/21 16:29
-- Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Posts Q4 Revenue $20.3M
-- Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Posts Q4 Revenue $20.3M
MT Newswires · 11/21 16:03
Earnings Scheduled For November 21, 2022
Benzinga · 11/21 10:50
Earnings Outlook For Enanta Pharmaceuticals
Benzinga · 11/18 15:01
Enanta starts mid-stage study of oral antiviral EDP-235 for COVID-19
Seekingalpha · 11/09 13:47
BRIEF-Enanta Pharmaceuticals Initiates Phase 2 Trial Of Its Covid-19 Treatment
Reuters · 11/09 12:30
Enanta Pharmaceuticals Initiates SPRINT, A Phase 2 Clinical Trial Of EDP-235, Its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed For The Treatment Of COVID-19
Benzinga · 11/09 12:11
Enanta Pharmaceuticals Begins Phase 2 Trial of EDP-235 in Mild COVID-19
Enanta Pharmaceuticals Begins Phase 2 Trial of EDP-235 in Mild COVID-19
MT Newswires · 11/09 11:41
Investors in Enanta Pharmaceuticals (NASDAQ:ENTA) have unfortunately lost 51% over the last year
The nature of investing is that you win some, and you lose some. Anyone who held Enanta Pharmaceuticals, Inc...
Simply Wall St. · 11/03 15:22
Enanta Pharmaceuticals Presents New Preclinical Data For EDP-235, Its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed For The Treatment Of COVID-19 At IDWeek 2022 On October 21
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new preclinical data supporting
Benzinga · 10/19 12:11
Enanta Pharmaceuticals Doses First Subject In A Phase 1 Clinical Study Of EDP-323, Its Novel, Oral L-Protein Inhibitor In Development For The Treatment Respiratory Syncytial Virus
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first subject
Benzinga · 10/17 11:09
Enanta Pharmaceuticals Doses First Subject in Clinical Study of EDP-323 to Treat Respiratory Syncytial Virus
Enanta Pharmaceuticals Doses First Subject in Clinical Study of EDP-323 to Treat Respiratory Syncytial Virus
MT Newswires · 10/17 07:36
--RBC Trims Price Target on Enanta Pharmaceuticals to $65 From $66, Maintains Sector Perform Rating
--RBC Trims Price Target on Enanta Pharmaceuticals to $65 From $66, Maintains Sector Perform Rating
MT Newswires · 10/06 07:50
Enanta starts mid-stage trial of EDP-938 for RSV infection
Enanta Pharmaceuticals (NASDAQ:ENTA) <a href="https:...
Seekingalpha · 10/03 14:57
BRIEF-Enanta Pharmaceuticals Initiates A Phase 2B Clinical Study Of EDP-938
BRIEF-Enanta Pharmaceuticals Initiates A Phase 2B Clinical Study Of EDP-938
Reuters · 10/03 11:16
More
Webull provides a variety of real-time ENTA stock news. You can receive the latest news about Enanta Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENTA
Enanta Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in development of small molecule drugs for the treatment of viral infections and liver diseases. The Company has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). The Company has discovered glecaprevir, a protease inhibitor discovered and developed for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET. Its product candidates also include EDP-514, EDP-305 and EDP-938. The Company's subsidiary is Enanta Pharmaceuticals Security Corporation.